Safety Observations With 3 Years of Denosumab Exposure: Comparison Between Subjects Who Received Denosumab During the Randomized FREEDOM Trial and Subjects Who Crossed Over to Denosumab During the FREEDOM Extension

Watts, N.B.; Brown, J.P.; Papapoulos, S.; Lewiecki, E.M.; Kendler, D.L.; Dakin, P.; ... ; Bone, H.G. (2017)

Article / Letter to editor

• DENOSUMAB
• PROLIA
• SAFETY
• OSTEOPOROSIS
• FRACTURE

• All authors: Watts, N.B.; Brown, J.P.; Papapoulos, S.; Lewiecki, E.M.; Kendler, D.L.; Dakin, P.; Wagman, R.B.; Wang, A.; Daizadeh, N.S.; Smith, S.; Bone, H.G.
• Date: 2017-07-31
• Journal: Journal of Bone and Mineral Research
• Volume: 32
• Issue: 7
• Pages: 1481 - 1485
• DOI: doi:10.1002/jbmr.3119